The Emerging Role of Cyclin-Dependent Kinase Inhibitors in Treating Diet-Induced Obesity: New Opportunities for Breast and Ovarian Cancers?

CDK inhibitors (CDKIs) CDK4/6 RB1 breast cancer cell-cycle inhibitors diet-induced obesity (DIO) ovarian cancer

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
30 May 2022
Historique:
received: 26 04 2022
revised: 26 05 2022
accepted: 26 05 2022
entrez: 10 6 2022
pubmed: 11 6 2022
medline: 11 6 2022
Statut: epublish

Résumé

Overweight and obesity constitute the most impactful lifestyle-dependent risk factors for cancer and have been tightly linked to a higher number of tumor-related deaths nowadays. The excessive accumulation of energy can lead to an imbalance in the level of essential cellular biomolecules that may result in inflammation and cell-cycle dysregulation. Nutritional strategies and phytochemicals are gaining interest in the management of obesity-related cancers, with several ongoing and completed clinical studies that support their effectiveness. At the same time, cyclin-dependent kinases (CDKs) are becoming an important target in breast and ovarian cancer treatment, with various FDA-approved CDK4/6 inhibitors that have recently received more attention for their potential role in diet-induced obesity (DIO). Here we provide an overview of the most recent studies involving nutraceuticals and other dietary strategies affecting cell-cycle pathways, which might impact the management of breast and ovarian cancers, as well as the repurposing of already commercialized chemotherapeutic options to treat DIO.

Identifiants

pubmed: 35681689
pii: cancers14112709
doi: 10.3390/cancers14112709
pmc: PMC9179653
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Nutrients. 2019 Oct 05;11(10):
pubmed: 31590362
Nat Commun. 2020 Jun 23;11(1):3083
pubmed: 32576828
Int J Mol Sci. 2019 Feb 15;20(4):
pubmed: 30781341
J Exp Med. 2020 Jan 6;217(1):
pubmed: 31727782
PLoS One. 2020 Apr 21;15(4):e0227256
pubmed: 32315295
Radiat Res. 2013 Jul;180(1):34-43
pubmed: 23745991
Mol Carcinog. 2013 Feb;52(2):134-43
pubmed: 22086611
Curr Pharmacol Rep. 2015 Nov 1;1(6):382-390
pubmed: 26557472
Cell Death Dis. 2021 Aug 3;12(8):763
pubmed: 34344865
Exp Ther Med. 2018 Aug;16(2):1266-1272
pubmed: 30116377
J Clin Oncol. 2019 Jan 20;37(3):178-189
pubmed: 30523750
Aging (Albany NY). 2017 Jun 12;9(6):1477-1536
pubmed: 28611316
Ann Oncol. 2005 Aug;16(8):1253-67
pubmed: 15870086
Cancer. 2015 May 1;121(9):1463-8
pubmed: 25522918
Oncologist. 2015 May;20(5):483-90
pubmed: 25876993
Cancers (Basel). 2019 Dec 12;11(12):
pubmed: 31842413
Histopathology. 2008 Oct;53(4):484-7
pubmed: 18983614
BMC Cancer. 2020 Jun 22;20(1):578
pubmed: 32571329
JAMA Oncol. 2020 Jan 01;6(1):116-124
pubmed: 31563959
Clin Cancer Res. 2018 Jul 1;24(13):2999-3004
pubmed: 29437768
Brain Behav Immun. 2020 Aug;88:815-825
pubmed: 32454134
Nature. 2014 Oct 2;514(7520):54-8
pubmed: 25079331
Front Oncol. 2022 Feb 10;11:810023
pubmed: 35223458
Int J Clin Oncol. 2019 Mar;24(3):262-273
pubmed: 30392115
World J Methodol. 2016 Mar 26;6(1):43-55
pubmed: 27019796
Trends Pharmacol Sci. 2007 Apr;28(4):162-5
pubmed: 17331592
Breast Cancer (Auckl). 2020 Jan 10;14:1178223419898458
pubmed: 31975779
Cancer Manag Res. 2018 Dec 05;10:6685-6693
pubmed: 30584363
Clin Cancer Res. 2015 Nov 15;21(22):5121-5130
pubmed: 25991817
J Mol Med (Berl). 2010 Jul;88(7):677-86
pubmed: 20339829
Mol Cancer Res. 2018 May;16(5):869-879
pubmed: 29453319
Nutrients. 2018 Aug 30;10(9):
pubmed: 30200193
Breast. 2021 Oct;59:321-326
pubmed: 34388698
Cell Metab. 2005 Oct;2(4):239-49
pubmed: 16213226
Breast Cancer Res. 2009;11(5):R77
pubmed: 19874578
J Adv Pract Oncol. 2020 Mar;11(2):135-136
pubmed: 33532112
Nat Commun. 2017 Jan 09;8:13923
pubmed: 28067227
Semin Oncol. 2002 Jun;29(3 Suppl 11):77-85
pubmed: 12138401
Cancer Res. 2008 Nov 1;68(21):8687-94
pubmed: 18974110
J Cell Biochem. 2011 Apr;112(4):1103-17
pubmed: 21308739
Phytomedicine. 2010 May;17(6):436-40
pubmed: 19800775
Oncotarget. 2016 Jan 12;7(2):1262-75
pubmed: 26556856
Front Immunol. 2022 Apr 20;13:859738
pubmed: 35514957
Nature. 2001 Jun 28;411(6841):1017-21
pubmed: 11429595
Cancers (Basel). 2021 Dec 14;13(24):
pubmed: 34944905
Int J Gynecol Cancer. 2006 Jan-Feb;16(1):219-21
pubmed: 16445636
Breast. 2016 Aug;28:191-8
pubmed: 27336726
Gynecol Oncol. 2013 May;129(2):353-7
pubmed: 23402904
J Transl Med. 2022 Mar 7;20(1):112
pubmed: 35255925
Cell Physiol Biochem. 2015;36(3):956-65
pubmed: 26087719
Front Endocrinol (Lausanne). 2017 Oct 30;8:293
pubmed: 29163362
Nat Rev Drug Discov. 2015 Feb;14(2):130-46
pubmed: 25633797
Oncogene. 2020 Jun;39(25):4896-4908
pubmed: 32472077
Drugs. 2017 Dec;77(18):2063-2070
pubmed: 29128965
Trials. 2016 Jul 29;17:368
pubmed: 27473440
Mol Pharmacol. 2015 Nov;88(5):846-52
pubmed: 26018905
Endocr Relat Cancer. 2011 Jul 11;18(4):491-503
pubmed: 21636700
Lancet Oncol. 2015 Jan;16(1):25-35
pubmed: 25524798
PLoS One. 2015 Oct 06;10(10):e0139598
pubmed: 26440936
PLoS Biol. 2022 Feb 24;20(2):e3001517
pubmed: 35202387
Eur J Cancer. 2011 Jul;47(10):1578-84
pubmed: 21353530
Cancer Invest. 2017 Jul 3;35(6):367-376
pubmed: 28406716
J Oncol. 2019 May 23;2019:6313242
pubmed: 31239840
Arch Gynecol Obstet. 2018 Sep;298(3):597-605
pubmed: 29974191
Clin Pharmacokinet. 2018 Mar;57(3):335-344
pubmed: 28540640
Pathol Res Pract. 2020 Apr;216(4):152902
pubmed: 32147274
Oncotarget. 2018 Feb 26;9(21):15658-15672
pubmed: 29644000
Br J Cancer. 2020 Sep;123(6):912-918
pubmed: 32641862
Endocr Relat Cancer. 2013 Mar 22;20(2):251-62
pubmed: 23404857
Lancet Oncol. 2019 Nov;20(11):1587-1601
pubmed: 31575503
Cancers (Basel). 2022 Mar 09;14(6):
pubmed: 35326545
Phytomedicine. 2020 Apr 18;70:153218
pubmed: 32335356
Breast Cancer Res. 2018 Nov 20;20(1):144
pubmed: 30458856
Int J Mol Sci. 2018 Feb 28;19(3):
pubmed: 29495598
Cell Oncol (Dordr). 2020 Feb;43(1):1-18
pubmed: 31900901
Lancet. 2020 Oct 17;396(10258):1160-1203
pubmed: 33069325
Cells. 2021 Jan 08;10(1):
pubmed: 33429846
Cancer Metastasis Rev. 2020 Sep;39(3):805-823
pubmed: 32385714
Breast Cancer Res Treat. 2020 Nov;184(1):23-35
pubmed: 32783178
Mol Nutr Food Res. 2019 May;63(9):e1801239
pubmed: 30690879
Nutr Rev. 2017 Jun 1;75(6):405-419
pubmed: 28969358
J Hematol Oncol. 2019 Sep 10;12(1):95
pubmed: 31500658
BMC Cancer. 2017 Nov 10;17(1):752
pubmed: 29126396
Anticancer Agents Med Chem. 2015;15(4):511-6
pubmed: 25544381
Nat Rev Endocrinol. 2014 Aug;10(8):455-465
pubmed: 24935119
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Cell Cycle. 2005 Sep;4(9):1201-15
pubmed: 16082211
Curr Oncol Rep. 2015;17(5):443
pubmed: 25716100
Cells. 2020 Jun 28;9(7):
pubmed: 32605277
Clin Cancer Res. 2017 Sep 1;23(17):5218-5224
pubmed: 28533223
Clin Cancer Res. 2016 Oct 15;22(20):4968-4972
pubmed: 27407089
Int J Mol Sci. 2020 Jun 04;21(11):
pubmed: 32512849
J Ovarian Res. 2021 Nov 11;14(1):153
pubmed: 34758846
Front Biosci. 2008 Jan 01;13:2191-202
pubmed: 17981702
Mod Pathol. 2011 Jun;24(6):801-9
pubmed: 21317876
BMC Cancer. 2015 Jul 01;15:492
pubmed: 26122176
Cancer Discov. 2016 Jul;6(7):740-53
pubmed: 27217383
Cancer Sci. 2020 May;111(5):1761-1773
pubmed: 32103527
Curr Opin Pharmacol. 2016 Dec;31:83-89
pubmed: 27816025
Invest New Drugs. 2014 Oct;32(5):825-37
pubmed: 24919854
Invest New Drugs. 1999;17(3):313-20
pubmed: 10665481
Cell Commun Signal. 2020 Mar 30;18(1):50
pubmed: 32228589
J Immunol. 2009 Oct 1;183(7):4169-75
pubmed: 19767566
Cancer Cell. 2017 Dec 11;32(6):761-776.e6
pubmed: 29232554
Curr Genomics. 2017 Apr;18(2):106-131
pubmed: 28367072
Mol Oncol. 2017 Jul;11(7):805-823
pubmed: 28599100
Mol Cell Endocrinol. 2014 Jan 25;382(1):570-582
pubmed: 23562747
Clin Cancer Res. 2013 Nov 15;19(22):6074-83
pubmed: 23958744
PLoS One. 2017 Dec 19;12(12):e0189233
pubmed: 29261726
BMC Complement Med Ther. 2020 Jan 13;20(1):1
pubmed: 32020859
Int J Oncol. 2016 Jun;48(6):2657-65
pubmed: 27082635
Trends Endocrinol Metab. 2020 Jan;31(1):46-52
pubmed: 31629614
Am J Pathol. 2011 Aug;179(2):1030-40
pubmed: 21704006
Sci Transl Med. 2014 Feb 5;6(222):222ra18
pubmed: 24500406
Cell Metab. 2016 Jun 14;23(6):1048-1059
pubmed: 27304506
Clin Cancer Res. 2020 Feb 1;26(3):566-580
pubmed: 31615937
Immunity. 2019 Apr 16;50(4):924-940
pubmed: 30995507
Gut. 2020 Jul;69(7):1269-1282
pubmed: 31685519
Cancer Res. 2017 Nov 15;77(22):6340-6352
pubmed: 28947417
Br J Clin Pharmacol. 2017 Jan;83(1):103-106
pubmed: 27016122
JCI Insight. 2018 Sep 6;3(17):
pubmed: 30185666
Cancer Immunol Immunother. 2018 Apr;67(4):537-549
pubmed: 29256156
Thorac Cancer. 2020 Apr;11(4):835-839
pubmed: 32043828
Oncologist. 2021 Jul;26(7):e1143-e1155
pubmed: 33955129
Mol Cancer Ther. 2018 Jun;17(6):1156-1166
pubmed: 29545334
Cancer Res. 2015 Jun 1;75(11):2375-2386
pubmed: 25840984
Microb Pathog. 2017 Nov;112:15-19
pubmed: 28882785
Endocrinology. 2018 Aug 1;159(8):3069-3080
pubmed: 29955847
N Engl J Med. 2020 Feb 6;382(6):514-524
pubmed: 31826360
Breast Cancer Res Treat. 2021 Feb;185(3):741-758
pubmed: 33179154
Cell Metab. 2014 Mar 4;19(3):407-17
pubmed: 24606898
Breast Cancer Res. 2000;2(2):116-24
pubmed: 11250701
Endocrine. 2013 Apr;43(2):394-403
pubmed: 22968658
Mol Cancer Ther. 2010 Aug;9(8):2344-53
pubmed: 20663931
Structure. 2012 Mar 7;20(3):487-97
pubmed: 22405007
Cell Cycle. 2014;13(4):553-64
pubmed: 24335340
Ann Oncol. 2021 Apr;32(4):488-499
pubmed: 33385521
Clin Cancer Res. 2015 Mar 1;21(5):995-1001
pubmed: 25501126
Clin Nutr. 2020 Aug;39(8):2389-2398
pubmed: 31735538
Nat Rev Cancer. 2011 Nov 24;11(12):886-95
pubmed: 22113164
Sci Transl Med. 2012 Mar 7;4(124):124ra27
pubmed: 22323820
Blood. 2017 Mar 30;129(13):1876-1878
pubmed: 28126927
Mol Cancer Ther. 2017 Sep;16(9):1739-1750
pubmed: 28572168
ESMO Open. 2020 Oct;5(5):e000926
pubmed: 33109627
Am J Clin Nutr. 2015 Mar;101(3):558-69
pubmed: 25733641
Cell Metab. 2018 Jan 9;27(1):136-150.e5
pubmed: 29249690
Cell Metab. 2016 Dec 13;24(6):835-847
pubmed: 27974179
J Clin Biochem Nutr. 2010 Jan;46(1):60-7
pubmed: 20104266
J Cell Mol Med. 2015 May;19(5):1122-32
pubmed: 25721149
Clin Cancer Res. 2017 Sep 15;23(18):5561-5572
pubmed: 28606920
Mol Nutr Food Res. 2021 Jun;65(12):e2100163
pubmed: 33939887
Trends Endocrinol Metab. 2018 Apr;29(4):271-280
pubmed: 29463451
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Invest New Drugs. 2015 Apr;33(2):480-9
pubmed: 25431127
J Breast Cancer. 2015 Sep;18(3):225-34
pubmed: 26472972
ScientificWorldJournal. 2014;2014:565839
pubmed: 25114970
Biotech Histochem. 2019 Jan;94(1):53-59
pubmed: 30264586
Int J Mol Med. 2018 Sep;42(3):1625-1636
pubmed: 29956731
Oncotarget. 2016 Sep 13;7(42):68012-68022
pubmed: 27634906
Breast Cancer Res Treat. 2020 Aug;183(1):153-160
pubmed: 32572715
Pharmacol Res. 2019 Mar;141:392-396
pubmed: 30639384
Cancer Res. 2019 Jul 1;79(13):3479-3491
pubmed: 31064851
J Clin Oncol. 2020 Dec 1;38(34):3987-3998
pubmed: 32954927
Cancers (Basel). 2021 Apr 08;13(8):
pubmed: 33917839
Clin Cancer Res. 2011 Mar 15;17(6):1591-602
pubmed: 21278246
Mol Carcinog. 2020 Jul;59(7):794-806
pubmed: 32212206
Biochem Biophys Res Commun. 2006 Jun 23;345(1):271-9
pubmed: 16678125
Front Chem. 2020 Jun 18;8:516
pubmed: 32626692
Cell Mol Life Sci. 2016 Apr;73(7):1457-77
pubmed: 26786898
Cancer Discov. 2020 Dec;10(12):OF3
pubmed: 33051239
J Clin Oncol. 2018 Aug 20;36(24):2465-2472
pubmed: 29860922
J Immunother Cancer. 2019 Jun 22;7(1):157
pubmed: 31228946
PLoS One. 2012;7(11):e49047
pubmed: 23145063
J Clin Oncol. 2017 Sep 1;35(25):2875-2884
pubmed: 28580882
Front Immunol. 2019 Apr 24;10:804
pubmed: 31105691
Trials. 2020 Oct 15;21(1):854
pubmed: 33059765
J Biol Chem. 1998 Feb 13;273(7):3838-47
pubmed: 9461564
Phytother Res. 2013 Dec;27(12):1790-4
pubmed: 23401195
Cancer Biol Med. 2016 Mar;13(1):101-19
pubmed: 27144066
Nat Rev Cancer. 2018 Nov;18(11):707-719
pubmed: 30327499

Auteurs

Reyes Benot-Dominguez (R)

Sbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.

Annamaria Cimini (A)

Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.

Daniela Barone (D)

Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, 80131 Napoli, Italy.

Antonio Giordano (A)

Sbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.
Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.

Francesca Pentimalli (F)

Department of Medicine and Surgery, LUM University, 70010 Bari, Italy.

Classifications MeSH